Evidence map›Paper›PMID 42239542›Full record

Observational studyFrontiers in cellular and infection microbiology2026

Early supplementation with live combined

Chaohui Ye, Li Li, Hongming Zhang, Qin Lyu, Yinquan Xu, Yanhong Li

Abstract readObservational Study
PubMed Full text at PMC Publisher
In one paragraph

Observational study in Frontiers in cellular and infection microbiology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Chaohui YeClinical Trial Institution, Women and Children's Hospital of Ningbo University, Ningbo, Zhejiang, China.
Li LiDepartment of Neonatal Intensive Care Unit, Women and Children's Hospital of Ningbo University, Ningbo, Zhejiang, China.
Hongming ZhangSchool of Bioengineering, East China University of Science and Technology, Shanghai, China.
Qin LyuDepartment of Neonatal Intensive Care Unit, Women and Children's Hospital of Ningbo University, Ningbo, Zhejiang, China.
Yinquan XuDepartment of Neonatal Intensive Care Unit, Women and Children's Hospital of Ningbo University, Ningbo, Zhejiang, China.
Yanhong LiSchool of Bioengineering, East China University of Science and Technology, Shanghai, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Early antibiotic exposure frequently induces gut dysbiosis in preterm infants. Although probiotics, such as the live combined preparation of Methods: Seventy-nine antibiotic-exposed preterm infants admitted to the neonatal intensive care unit (NICU) between February 2020 and April 2022 were enrolled and divided into two groups based on clinical LCBE administration: the probiotic group (n = 41) and the non-probiotic group (n = 38). Clinical data were collected prospectively. Gut microbiota composition was analyzed via 16S rRNA gene sequencing of 274 fecal samples (144 from the probiotic group, 130 from the non-probiotic group). Results: LCBE supplementation was associated with a significantly lower incidence of FI (17.07% vs. 44.74%; adjusted OR = 0.156, 95% CI: 0.050-0.491, Conclusions: In antibiotic-exposed preterm infants, early LCBE supplementation was associated with a significant reduction in the incidence of feeding intolerance. This clinical benefit was accompanied by favorable gut microbiota modulation, characterized by the suppression of opportunistic pathogen overgrowth and the preservation of beneficial commensal taxa. These findings support the potential role of LCBE as a safe and well-tolerated adjunctive intervention in this vulnerable population, offering practical insights for neonatologists.

Indexed as

Anti-Bacterial AgentsBacillus subtilisDysbiosisEnterococcus faeciumGastrointestinal MicrobiomeProbioticsDietary SupplementsFecesFemaleHumansInfant, NewbornInfant, PrematureIntensive Care Units, NeonatalMaleProspective StudiesRNA, Ribosomal, 16SAnti-Bacterial AgentsRNA, Ribosomal, 16Santibiotic exposurefeeding intolerancegut microbiotapreterm infantsprobiotics

Identifiers

PMID42239542
PMCPMC13226532

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.